Phosphodiesterase III and V inhibitors on pulmonary artery from pulmonary hypertensive rats: Differences between early and established pulmonary hypertension

Journal of Cardiovascular Pharmacology

Volumn 32, Issue 2, 1998, Pages 213-219

  Jeffery, Trina K ^a   Wanstall, Janet C ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Forskolin; Hypoxia Pulmonary vascular function; Phosphodiesterase inhibitors; Pulmonary hypertension

Indexed keywords

6 BROMO 8 METHYLAMINOIMIDAZO[1,2 A]PYRAZINE 2 CARBONITRILE; ISOBUTYLMETHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE INHIBITOR; ZAPRINAST;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; NONHUMAN; PRIORITY JOURNAL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; VASOCONSTRICTION;

1-METHYL-3-ISOBUTYLXANTHINE; 3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ANIMALS; ANOXIA; FEMALE; FORSKOLIN; HYPERTENSION, PULMONARY; IMIDAZOLES; MALE; MILRINONE; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; PULMONARY ARTERY; PYRAZINES; PYRIDONES; RATS; RATS, WISTAR; VASODILATION;

EID: 0031875353     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199808000-00007     Document Type: Article

References (31)

1. Reid LM. Hypoxia and hyperoxia: patterns in vascular remodelling and cell adaptation. Prog Respir Res 1990;26:12-28.
2. Vender RL. Chronic hypoxic pulmonary hypertension; cell biology to pathophysiology. Chest 1994;106:236-43.
3. Voelkel NF, Tuder RM. Cellular and molecular mechanisms in the pathogenesis of severe pulmonary hypertension. Eur Respir J 1995;8:2129-38.
4. Salvaterra CG, Rubin LJ. Investigation and management of pulmonary hypertension in chronic obstructive pulmonary disease. Am Rev Respir Dis 1993;148:1414-7.
5. Rubin LJ. The medical management of pulmonary hypertension. In: Morice AH, ed. Clinical pulmonary hypertension. London: Portland Press, 1995:235-45.
6. Dinh-Xuan AT, Higenbottam TW, Clelland TW, et al. Impairment of endothelium-dependent pulmonary artery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539-47.
7. Wanstall JC, Kay CS, O'Donnell SR. Pinacidil-induced relaxation in pulmonary arteries isolated from pulmonary hypertensive and normotensive rats and precontracted with different spasmogens. Pulm Pharmacol 1994;7:401-8.
8. Wanstall JC, Hughes IE, O'Donnell SR. Reduced relaxant potency of nitroprusside on pulmonary artery preparations taken from rats during the development of hypoxic pulmonary hypertension. Br J Pharmacol 1992;107:407-13.
9. Wanstall JC, Kaye JA, Gambino A. The in vitro pulmonary vascular effects of FK409 (nitric oxide donor): a study in normotensive and pulmonary hypertensive rats. Br J Pharmacol 1997;121:280-6.
10. Crawley DE, Zhao L, Giembycz MA, et al. Chronic hypoxia impairs soluble guanylyl cyclase-mediated pulmonary arterial relaxation in the rat. Am J Physiol 1992;263:L325-32.
11. + channel-mediated relaxation. Am J Physiol 1992;263:L88-94.
12. Rabe KF, Tenor H, Dent G, Schudt C, Nakashima M, Magnussen H. Identification of PDE isozymes in human pulmonary artery and effect of selective PDE inhibitors. Am J Physiol 1994;266:L536-43.
13. Cook SJ, Martin A, Buchheit K, et al. Further analysis of the mechanisms underlying the tracheal relaxant action of SCA40. Br J Pharmacol 1995;114:143-51.
14. Cortijo J, Villagrassa, V, Navarrete C, et al. Effects of SCA40 on human isolated bronchi and human polymorphonuclear leukocytes: comparison with rolipram and levcromakalim. Br J Pharmacol 1996;119:99-106.
15. Crilley TK, Wanstall JC. A comparative study of inhibitors of phosphodiesterases III and V in pulmonary arteries from pulmonary hypertensive and normotensive rats. Proc Aust Soc Clin Exp Pharmacol Toxicol 1996;3:91.
16. Wanstall JC, Crilley TK. Phosphodiesterase inhibitors on pulmonary arteries from rats with hypoxic pulmonary hypertension: comparison of 1 and 4 weeks hypoxia. Br J Pharmacol Suppl 1997;12:375p.
17. Wanstall JC, O'Donnell SR. Responses to vasodilator drugs on pulmonary artery preparations from pulmonary hypertensive rats. Br J Pharmacol 1992;105:152-8.
18. Wanstall JC, Hughes IE, O'Donnell SR. Evidence that nitric oxide from the endothelium attenuates inherent tone in isolated pulmonary arteries from rats with hypoxic pulmonary hypertension. Br J Pharmacol 1995;114:109-14.
19. Wanstall JC, Crilley TK. Relaxation of rat pulmonary artery by adrenomedullin involves endothelium-derived nitric oxide and is attenuated in hypoxic pulmonary hypertension. Pharmacol Commun 1996;7:349-56.
20. Martin W, Furchgott RF, Villani GM, Jothianandan D. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor. J Pharmacol Exp Ther 1986;237:539-47.
21. Harris A, Lemp B, Bentley R, Perrone M, Hamel L, Silver P. Phosphodiesterase isozyme inhibition and the potentiation by zaprinast of endothelium-derived relaxing factor and guanylate cyclase stimulating agents in vascular smooth muscle. J Pharmacol Exp Ther 1989;249:394-400.
22. Komas N, Lugnier C, Stoclet JC. Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br J Pharmacol 1991;104:495-503.
23. McMahon TJ, Ignarro LJ, Kadowitz PJ. Influence of zaprinast on vascular tone and vasodilator responses in the cat pulmonary vascular bed. J Appl Physiol 1993;74:1704-11.
24. Braner DAV, Fineman JR, Chang R, Soifer SJ. M & B 2948, a cGMP phosphodiesterase inhibitor, is a pulmonary vasodilator in lambs. Am J Physiol 1993;264:H252-8.
25. υ-nitro-L-arginine attenuates the accumulation of aortic cyclic GMP and the hypotension produced by zaprinast. Eur J Pharmacol 1991;200: 83-7.
26. Reid L. The pulmonary circulation: remodelling in growth and disease. Am Rev Respir Dis 1979;119:531-46.
27. MacLean MR, Sweeney G, Baird K, McCulloch KM, Houslay M, Morecroft I. 5-Hydroxytryptamine receptors mediating vasoconstriction in pulmonary arteries from control and pulmonary hypertensive rats. Br J Pharmacol 1996;119:917-30.
28. Twarog BM, Takuno H, Petrou S, Wahlqvist I, Marcus R, Campbell GL. Pathogenesis of pulmonary hypertension in the rat model. Chest 1988;93:100-15.
29. Wagenvoort CA, Wagenvoort N. Pathology of pulmonary hypertension. New York: Wiley, 1977.
30. MacClean MR, Johnston ED, McCulloch KM, Pooley L, Houslay MD, Sweeney G. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997;283:619-24.
31. Rhoades R, Whittle E. Selective inhibition of hypoxia on rat lung cyclic AMP. Respir Physiol 1978;35:59-63.